Drugs / oxacillin
oxacillin
also known as
Anhydrous oxacillin sodium · Bactocill · Bristopen · Cryptocillin · Micropenin · NSC-527712 · NSC-757253 · Oxacilina · +13 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | OXACILLIN SODIUM | — | 1971-04-08 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00037050 | Apr 2002 → Jul 2005 | gram-positive bacterial infections | Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05156437 | Mar 2022 → Oct 2024 | endocarditis | West Virginia University | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 17 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06616168 Background | Sep 2023 → Aug 2026 overdue | bacterial vaginosis | Danylo Halytsky Lviv National Medical University | Active not recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04775953 Comparator | Apr 2021 → Oct 2023 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01756924 Comparator | Dec 2012 → Jul 2014 | periprosthetic joint infection | Arrevus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00428844 Comparator | Jun 2007 → Mar 2010 | osteomyelitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00077675 Comparator | Feb → Sep 2004 | gram-positive bacterial infections | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00062647 Comparator | Aug 2003 → Aug 2006 | gram-positive bacterial infections | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00061633 Comparator | Jun 2003 → Jan 2004 | abscess, cellulitis, gram-positive bacterial infections, ulcer disease | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT02814916 Comparator | Mar 2017 → Jan 2024 | methicillin-resistant staphylococcus aureus infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02344511 Comparator | Mar 2016 → Oct 2018 | osteomyelitis | Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | Withdrawn | No outcome recorded |
| Phase 3 | NCT02208063 Comparator | Dec 2014 → Apr 2018 | bacterial infectious disease | Cumberland Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01184872 Comparator | Mar 2010 → Mar 2011 | skin infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07148960 Comparator | Sep 2025 → Jul 2027 expected | staphylococcus aureus infection | West Virginia University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05977868 Comparator | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT01104662 Comparator | Apr 2010 → Jun 2012 | impaired renal function disease, staphylococcus aureus infection | Merck & Co., Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00711802 Comparator | Jul 2008 → Oct 2013 | skin disease caused by bacterial infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01166932 Comparator | Apr 2005 → Apr 2007 | pneumonia | UPECLIN HC FM Botucatu Unesp | Completed | No outcome recorded |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oxacillin | “Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up...” NCT00061633 ↗18“nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.” NCT00077675 ↗ “meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin” NCT05977868 ↗ “Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin.” NCT07148960 ↗ “penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin)” NCT01104662 ↗ “nafcillin, oxacillin, cloxacillin” NCT00711802 ↗ “Oxacillin,” NCT01184872 ↗ “Oxacillin” NCT02208063 ↗ “Oxacillin” NCT02099240 ↗ |
| Known as | Anhydrous oxacillin sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Bactocill | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Bristopen | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Cryptocillin | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Micropenin | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | NSC-527712 | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | NSC-757253 | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Oxacilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | OXACILLIN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Oxacillin sodium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Oxacillin sodium monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Oxacillin sodium salt monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Oxacilline | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Oxazocilline | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Penicillin p-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Penstapho | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Prostaphlin | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | SO 16,423 | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Sodium oxacillin | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | SQ 16,423 | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Known as | Stapenor | ChEMBL registry synonym — accepted as the source's own label CHEMBL819 ↗ |
| Modality | Small molecule | — CHEMBL819 ↗ |
| Route | Intravenous | “nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs” NCT00061633 ↗ |